BCTX News & Events

BriaCell Therapeutics announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research, AACR, Annual Meeting, taking place April 17-22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell's ongoing Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, and two posters highlighting further analyses of Phase 2 data. Abstracts will be published in the online Proceedings of the AACR. "Standards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell's, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety," stated lead author, Saranya Chumsri, MD, Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic.

BriaCell and its majority-owned subsidiary BriaPro Therapeutics announced that they have entered into a definitive purchase agreement pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer and other associated assets. Under the terms of the Purchase Agreement, BriaPro gains the worldwide rights to develop and commercialize sCD80 as a therapeutic agent for the treatment of cancer, while UMBC holds all rights, title and interest in the inventions and the patent, except for certain rights retained by the United States Government. BriaPro will pay 2% royalties to UMBC upon the commercialization of the product plus other development costs. As part of the Transaction, BriaCell will make available to BriaPro up to $3M to fund research and development efforts. Each drawdown under the Credit Facility will be subject to BriaCell's approval regarding the use of funds. As consideration for the transfer of the exclusive license and the Credit Facility, BriaPro will issue to BriaCell 23,972,589 Common Shares at an aggregate value of approximately C$1.18M, increasing BriaCell's interest in BriaPro to approximately 78% post-transaction. The Transaction is expected to close on or around March 12, 2026, subject to certain conditions including (i) approval of the disinterested shareholders of BriaPro, and (ii) receipt of a third-party valuation confirming that the Transaction is occurring at fair market value. In accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, the resolution approving the Purchase Agreement must be approved by a simple majority of votes cast by shareholders, present in person or represented by proxy and entitled to vote at the Meeting, excluding the votes cast by any "interested party." As a 10% shareholder with an interest in the Transaction, BriaCell's shareholdings in BriaPro will be excluded from voting.

BriaCell Therapeutics announces that the independent Data Safety Monitoring Board, DSMB, has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor, CPI, in patients with metastatic breast cancer. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell's ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer.